Investors

To invest in Neola Medical

At Neola Medical, our vision is to ensure preterm born babies worldwide have a better start in life. Through our groundbreaking medical device, Neola®, we aim to transform neonatal intensive care by offering non-invasive, continuous, real-time lung monitoring. This technology enables the immediate detection of life-threatening complications, supporting proactive care, reducing morbidity, and improving the quality of life for these vulnerable patients.

Neola® is specifically designed to address the critical needs of preterm born babies, positioning Neola Medical as a leader in a the growing and non-cyclical pediatric medical device market. By utilizing patented GASMAS technology, Neola® continuously measures lung volume changes and oxygen gas concentration, allowing healthcare professionals to detect complications such as airway obstructions or lung collapse instantly—well before they become apparent through current methods.

Neola Medical is proud to be one of the few companies selected for the Stanford University Impact1 program, which supports the market reach of medical technology innovations designed for children. Neola® has been recognized by leading experts in neonatology at Stanford as a promising innovation with the potential to upgrade neonatal intensive care from the first day in the clinic.

As we approach the commercial launch of Neola®, we are focused on obtaining market approval in the USA followed by Europe. Supported by a strong tradition of Swedish medical technology innovation, Neola® has the potential to set a new standard of care, saving lives and significantly improving outcomes for preterm born babies worldwide.

Information about risks and uncertainties at our website here.